Compare Endeavour Silver Corp (EXK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Endeavour Silver Corp trades at $8.83 (market cap $2.54B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 50.2× Endeavour Silver Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EXK | VRTX | |
|---|---|---|
Market Cap | $2.54B | $127.55B |
Volume | 7,077,330 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $557.96 |
52-Week Low | $7.07 | $407.37 |
Typical Hold Time | 25 Days | 120 Days |
Enterprise Value | $2.54B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% today, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, matching estimates with $0.15 EPS, but showed strong revenue growth and improved profitability in 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though temporary disruptions occurred. Analyst consensus remains strongly bullish with a $10.50 price target.
Outlook is cautiously optimistic driven by production growth and favorable metal prices, but risks include operational disruptions and high valuation multiples. The stock offers potential upside from current levels if execution continues, but volatility from commodity prices and mine-specific issues persists.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
